Long‐term efficacy and safety of zanubrutinib (ZANU) in relapsed/refractory marginal zone lymphoma (R/R MZL): final analysis of the MAGNOLIA (BGB‐3111‐214) trial.

Authors :: Trotman, J.
Tedeschi, A.
Hu, B.
Linton, K. M.
McKay, P.
Leitch, S.
Jin, J.
Sun, M.
Sobieraj‐Teague, M.
Zinzani, P. L.
Browett, P.
Thieblemont, C.
Liberati, A. M.
Bachy, E.
Cavallo, F.
Costello, R.
Iyengar, S.
Marasca, R.
Mociková, H.
Kim, J. S.
Source :: Hematological Oncology; Jun2023 Supplement 1, Vol. 41, p390-392, 3p
Publication Year :: 2023
Abstract: B Introduction: b ZANU (BGB-3111), a potent next-generation Bruton tyrosine kinase inhibitor, is approved in various countries for R/R MZL based on the MAGNOLIA study (NCT03846427) primary analysis. Efficacy was assessed by positron emission tomography (PET)-based Lugano criteria for pts with IRC-confirmed fluorodeoxyglucose (FDG)-avid disease at baseline; non-avid pts were assessed by computed tomography (CT)-based criteria. [Extracted from the article]

Subjects :: MUCOSA-associated lymphoid tissue lymphoma
BRUTON tyrosine kinase
MAGNOLIAS

Full Text Access

Tools